Lead Sponsor

University of Chicago

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients must have histologically confirmed, unresected cancer of the pancreas or ampulla. The cancer may include any invasive histology (e.g. adenocarcinoma, neuroendocrine carcinoma).
•Patients may receive any number of cycles of chemotherapy prior to treatment with SBRT, but not within 2 weeks of the first fraction of RT.
•Age \> or = 18 years.
•Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 (Karnofsky \> or = 60%)
•Life expectancy of greater than 3 months.
•Patients must have normal organ and marrow function.
•Ability to understand and the willingness to sign a written informed consent document.

•Concurrent investigational therapy delivered over the period of treatment or observation (28 days post-RT) for dose limiting toxicity.
•Prior radiation therapy to the abdominal area which would overlap with the proposed area of treatment.
•Pregnancy.
•Primary disease \> 7.5 cm in largest diameter as measured by CT or MRI.
•Gross extension of tumor into the lumen of the duodenum.
•Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
•Use of bevacizumab or vascular endothelial growth factor inhibitor chemotherapy within 3 months before RT or 6 months after RT.

Related studies

NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more

NCT07542041 · Pancreatic Cancer, Pancreatic Neoplasms, and more

NCT07283705 · Phase 2 Study, BMS-986504, and more

Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer